[Federal Register Volume 66, Number 107 (Monday, June 4, 2001)]
[Notices]
[Page 29977]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-13886]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

PRAC & PRAC-Y: Small Nuclear Proteins Found in Prostate and Colon 
Cancer, and Uses Thereof

Ira Pastan et al. (NCI)
DHHS Reference No. E-053-01/0, filed 09 Apr 2001
Licensing Contact: Richard Rodriguez; 301/496-7056, ext. 287; e-mail: 
[email protected]

    Prostate cancer is the most commonly diagnosed cancer and the 
second leading cause of cancer death in males in the United States. 
Currently, there are no curative therapies available for this cancer 
and therefore, novel approaches are needed to treat this disease. The 
present invention claims a small, nuclear protein, PRAC (Prostate/
Rectum And Colon Protein) that could be used to diagnose and/or treat 
prostate or colon cancers. In conjunction with the composition of 
matter claims, defined methods of use might include: (1) Immunogenic 
fragments to elicit T cell responses against cells that express PRAC; 
(2) gene therapy applications through the use of appropriate expression 
vectors containing the nucleic acid sequences of PRAC; (3) detection 
and potential staging of cancers expressing PRAC. These disclosed 
technologies could provide new and exciting methodologies to treat 
prostate and/or colon cancer.

Biologically Active Macrolides, Compositions and Uses Thereof

Michael R. Boyd (NCI), Kirk R. Gustafson (NCI), and Charles L. Cantrell 
(USDA)
DHHS Reference No. E-203-00/0, filed 24 Jul 2000
Licensing Contact: Elaine White; 301/496-7056, ext. 282; e-mail: 
[email protected]

    The current invention embodies the identification of a novel class 
of potent vacuolar-type (H+)-ATPase-inhibitory compounds. Vacuolar-type 
(H+)-ATPases are present in many tissues and cells of the body and are 
involved in the maintenance of various physiological functions. The 
modification of these functions, via inhibition of vacuolar-type (H+)-
ATPases, may represent an effective means of treating various disease 
states, including Alzheimer's disease, glaucoma, and osteoporosis. In 
addition, these inhibitors may also be of particular value for use 
against cancer, as vacuolar-type (H+)-ATPases have been implicated in 
processes relating to cellular proliferation, angiogenesis, tumor cell 
invasiveness, metastasis, and drug resistance.

    Dated: May 24, 2001.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 01-13886 Filed 6-1-01; 8:45 am]
BILLING CODE 4140-01-P